SOURCE: Barrier Therapeutics, Inc.

September 01, 2005 10:00 ET

Barrier Therapeutics to Present at Roth Capital Partners New York Conference

PRINCETON, NJ -- (MARKET WIRE) -- September 1, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Al Altomari, Chief Commercial Officer of Barrier Therapeutics, is scheduled to provide an update on the Company at the Roth Capital Partners New York Conference. The conference is being held from September 7-8, 2005, at the Westin New York at Times Square in New York. Mr. Altomari is scheduled to present on Thursday, September 8th at 2:30 pm Eastern Time.

Mr. Altomari's presentation will also be available live via a webcast that can be accessed through the Company's website:

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and recently obtained the Canadian distribution rights for Vaniqa® (eflornithine hydrochloride) Cream 13.9% for slowing the growth of unwanted facial hair in women. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include one for the treatment of diaper dermatitis complicated by candidiasis, which is under FDA review, and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, onychomycosis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey, and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada.

Web site:

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Emily Poe